Dynamic Optical Breast Imaging (DOBI®) Technology Exhibited at South American Medical Conference
Mahwah, NJ, April 18, 2004
– DOBI Medical International, Inc. (DBMI.OB) announced today their
Dynamic Optical Breast Imaging (DOBI®) technology, commercially known as
the ComfortScan® system, will be featured at the 35th Jornada Paulista
de Radiologia (JPR) Conference, April 21-24, at the ITM Convention
Center in Sao Paulo, Brazil. The system will be displayed in the
Advanced Imaging, Ltd. exhibition booth (#65). One of the largest
radiology conferences in the region, the JPR Conference draws
approximately 8,000 people from around the world.
About DOBI Medical International, Inc.
DOBI Medical is a microcap, developmental stage, medical imaging company working to create a new means for the improved diagnosis of cancer through the detection of abnormal vascularization ("angiogenesis") associated with tumors. DOBI Medical International’s first application of the technology is the ComfortScan system, a gentle, noninvasive, and non-ionizing, optical imaging system designed to assist physicians in the detection and management of breast cancer. The ComfortScan system is intended to achieve this by providing new, physiology-based imagery of abnormal vascularization in the breast that is not readily available today. The ComfortScan system has its CE Mark and UL for international sales, and DOBI Medical is a certified ISO 9001:2000 and ISO 13485 company. The ComfortScan system is not yet commercially available in the U.S. as it is limited by U.S. law to investigational use as an adjunct to mammography until approved by the FDA, which cannot be guaranteed.
CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS
Statements contained in this press release may contain
information that includes or is based upon certain "forward-looking
statements" relating to our business. These forward-looking statements
represent management's current judgment and assumptions, and can be
identified by the fact that they do not relate strictly to historical or
current facts. Forward-looking statements are frequently accompanied by
the use of such words as "anticipates," "plans," "believes," "expects,"
"projects," "intends," and similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties, and other
factors, including without limitation, those relating to our ability to
timely and successfully complete our patient clinical trials; our
ability to timely and successfully complete and submit our premarket
approval application to the FDA; the timely and final approval by the
FDA of our ComfortScan system as a adjunct to mammography, which
approval in the U.S. cannot be assured; the success of product
development and research efforts; our ability to timely meet U. S. and
foreign government laws and industry standards; our ability to meet U.S.
and foreign medical device quality regulation standards required to
maintain our CE Mark, and ISO, UL and FDA export certifications; our
ability to timely deliver our products into international markets; the
acceptance and use of our ComfortScan system by physicians, imaging
clinics, and patients; and our ability to obtain third party
reimbursement from U.S. and foreign government and private payers.
For further information:
DOBI Medical International